Stocks › HALO

HALOZYME THERAPEUTICS, INC.

HALO·Nasdaq·United States United States·USD
$91.35
-1.69 (-1.82%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
HALO
HALOZYME THERAPEUTICS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
HALOS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of HALO by members of U.S. Congress · 11 on record · 2 in the last 12 months
All congressional trades →
PoliticianStockTypeFiledTraded
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA HALOHALOZYME THERAPEUTICS, INC. · Stock Sale
$1,001 - $15,000
Oct 12, 2026 Sep 29, 2026 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA HALOHALOZYME THERAPEUTICS, INC. · Stock Purchase
$1,001 - $15,000
Apr 7, 2026 Mar 9, 2026 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA HALOHALOZYME THERAPEUTICS, INC. · Stock Sale
$1,001 - $15,000
Apr 7, 2025 Mar 24, 2025 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ HALOHALOZYME THERAPEUTICS, INC. · Stock Sale
$1,001 - $15,000
Oct 3, 2024 Sep 9, 2024 Filing ↗
Daniel S. GoldmanDaniel S. GoldmanHouse · D · NY HALOHALOZYME THERAPEUTICS, INC. · Stock Sale
$15,001 - $50,000
Aug 13, 2023 Jul 12, 2023 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ HALOHALOZYME THERAPEUTICS, INC. · Stock Sale
$1,001 - $15,000
Jan 13, 2023 Dec 6, 2022 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ HALOHALOZYME THERAPEUTICS, INC. · Stock Sale
$1,001 - $15,000
Sep 16, 2022 Aug 5, 2022 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ HALOHALOZYME THERAPEUTICS, INC. · Stock Purchase
$1,001 - $15,000
Sep 20, 2021 Aug 20, 2021 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ HALOHALOZYME THERAPEUTICS, INC. · Stock Purchase
$1,001 - $15,000
Nov 5, 2020 Oct 19, 2020 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA HALOHALOZYME THERAPEUTICS, INC. · Stock Purchase
$1,001 - $15,000
Nov 5, 2020 Oct 22, 2020 Filing ↗
Mark R. WarnerMark R. WarnerSenate · D · VA HALOHALOZYME THERAPEUTICS, INC. · Stock Sale
$500,001 - $1,000,000
Dec 8, 2017 Nov 6, 2017 Filing ↗

Whale Activity

Position changes in HALO reported for 2026-09-30 by 824 institutional filers
Increased: 247New: 157Held: 95Decreased: 243Closed: 47No prior filing: 35
  • Increased247
  • New157
  • Held95
  • Decreased243
  • Closed47
  • No prior filing35
FilerSharesValueChange
BlackRock, Inc.13.7M$1.51Bincreased
VANGUARD CAPITAL MANAGEMENT LLC5.1M$563.8Mdecreased
STATE STREET CORP5.1M$559.0Mdecreased
VANGUARD PORTFOLIO MANAGEMENT LLC5.0M$550.6Mdecreased
Invesco Ltd.3.5M$390.2Mincreased
TWO SIGMA INVESTMENTS, LP3.5M$388.5Mincreased
D. E. Shaw & Co., Inc.3.4M$372.4Mincreased
MORGAN STANLEY2.9M$314.7Mincreased
Boston Partners2.8M$305.1Mdecreased
GEODE CAPITAL MANAGEMENT, LLC2.4M$266.6Mdecreased
BANK OF AMERICA CORP /DE/2.4M$262.0Mdecreased
CONGRESS ASSET MANAGEMENT CO2.3M$251.9Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by HALO insiders, by quarter · Form 4
-250.0K-125.0K0125.0K250.0K2025 Q1: -41.7K2025 Q12025 Q2: -65.0K2025 Q22025 Q3: -206.2K2025 Q32025 Q4: -145.7K2025 Q42026 Q1: -130.9K2026 Q12026 Q2: -160.6K2026 Q22026 Q3: -144.2K2026 Q32026 Q4: -130.2K2026 Q4

Recent Insider Transactions

2,159 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Posard Matthew L.Director · Director Sale −3,400 $96.17 $327K Nov 18, 2026 Form 4 ↗
Posard Matthew L.Director · Director Sale −1,600 $96.97 $155K Nov 18, 2026 Form 4 ↗
Torley HelenPRESIDENT AND CEO · Director Sale −7,283 $96.85 $705K Nov 16, 2026 Form 4 ↗
Torley HelenPRESIDENT AND CEO · Director Sale −4,897 $100.10 $490K Nov 16, 2026 Form 4 ↗
Torley HelenPRESIDENT AND CEO · Director Sale −4,802 $97.95 $470K Nov 16, 2026 Form 4 ↗
Torley HelenPRESIDENT AND CEO · Director Sale −188 $101.72 $19K Nov 16, 2026 Form 4 ↗
Torley HelenPRESIDENT AND CEO · Director Sale −1,586 $98.89 $157K Nov 16, 2026 Form 4 ↗
Torley HelenPRESIDENT AND CEO · Director Sale −1,244 $101.06 $126K Nov 16, 2026 Form 4 ↗
Torley HelenPRESIDENT AND CEO · Director Sale −7,992 $100.02 $799K Nov 13, 2026 Form 4 ↗
Torley HelenPRESIDENT AND CEO · Director Sale −12.0K $100.61 $1.2M Nov 13, 2026 Form 4 ↗
Torley HelenPRESIDENT AND CEO · Director Sale −9,289 $101.49 $943K Nov 12, 2026 Form 4 ↗
Torley HelenPRESIDENT AND CEO · Director Sale −10.7K $101.09 $1.1M Nov 12, 2026 Form 4 ↗
Torley HelenPRESIDENT AND CEO · Director Sale −4,810 $108.18 $520K Oct 8, 2026 Form 4 ↗
Torley HelenPRESIDENT AND CEO · Director Sale −3,090 $108.91 $337K Oct 8, 2026 Form 4 ↗
Torley HelenPRESIDENT AND CEO · Director Sale −200 $110.51 $22K Oct 8, 2026 Form 4 ↗
Torley HelenPRESIDENT AND CEO · Director Sale −11.9K $110.00 $1.3M Oct 8, 2026 Form 4 ↗
Torley HelenPRESIDENT AND CEO · Director Sale −900 $112.78 $102K Oct 7, 2026 Form 4 ↗
Torley HelenPRESIDENT AND CEO · Director Sale −8,600 $111.03 $955K Oct 7, 2026 Form 4 ↗
Torley HelenPRESIDENT AND CEO · Director Sale −200 $113.69 $23K Oct 7, 2026 Form 4 ↗
Torley HelenPRESIDENT AND CEO · Director Sale −10.3K $111.84 $1.2M Oct 7, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding HALO · SEC Form N-PORT
FundSharesValue% of fundAs of
iShares Core S&P Mid-Cap ETF
iShares Trust
4.1M$317.7M0.26%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
3.8M$294.5M0.01%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
2.7M$213.0M0.11%Jun 30, 2026
Invesco Discovery Fund
AIM Counselor Series Trust (Invesco Counselor Series Trust)
1.4M$147.3M1.99%Aug 31, 2026
VANGUARD SMALL-CAP GROWTH INDEX FUND
VANGUARD INDEX FUNDS
1.6M$122.6M0.26%Jun 30, 2026
Disciplined Value Mid Cap Fund
John Hancock Funds III
1.4M$112.0M0.48%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
1.4M$110.5M1.03%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.4M$106.4M0.11%Jun 30, 2026
First Trust NYSE Arca Biotechnology Index Fund
First Trust Exchange-Traded Fund
1.1M$87.6M3.11%Jun 30, 2026
FULLERTHALER BEHAVIORAL SMALL-CAP GROWTH
Capitol Series Trust
968.8K$75.8M1.23%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list HALO's shares (CUSIP 40637H109), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings

No 13D/13G beneficial-ownership filings on record.

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming halozyme therapeutics as client
$0$63K$125K$188K$250K2023 Q2: $20K2023 Q3: $60K2023 Q4: $60K20232024 Q1: $60K2024 Q2: $60K2024 Q3: $60K2024 Q4: $60K20242025 Q1: $60K2025 Q2: $60K2025 Q3: $60K2025 Q4: $60K20252026 Q1: $70K2026 Q2: $80K2026 Q3: $80K2026
  • FORBES-TATEHALOZYME THERAPEUTICS, INC. · 2026 Q3 · HCR, MMM$80K
    Filing ↗
  • FORBES-TATEHALOZYME THERAPEUTICS, INC. · 2026 Q2 · MMM, HCR$80K
    Filing ↗
  • FORBES-TATEHALOZYME THERAPEUTICS, INC. · 2026 Q1 · HCR, MMM$70K
    Filing ↗
  • FORBES-TATEHALOZYME THERAPEUTICS, INC. · 2025 Q4 · HCR, MMM$60K
    Filing ↗
  • FORBES-TATEHALOZYME THERAPEUTICS, INC. · 2025 Q3 · HCR, MMM$60K
    Filing ↗

Government Contracts

Federal awards to HALOZYME THERAPEUTICS, INC. · USAspending

No federal contract awards found for HALOZYME THERAPEUTICS, INC..

U.S. Patents

Recent USPTO applications naming HALOZYME THERAPEUTICS, INC.

No USPTO patent applications found for HALOZYME THERAPEUTICS, INC..

Annual Financials

From HALO's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$1.40B$1.02B$829.3M$660.1M$443.3M
Operating income$469.0M$551.5M$337.6M$267.5M$275.9M
Net income$316.9M$444.1M$281.6M$202.1M$402.7M
Diluted EPS$2.56$3.43$2.10$1.44$2.74
Operating cash flow$651.6M$479.1M$388.6M$240.1M$299.4M
Cash and equivalents$133.8M$115.8M$118.4M$234.2M$118.7M
Total assets$2.53B$2.06B$1.73B$1.84B$1.10B
Total liabilities$2.48B$1.70B$1.65B$1.67Bn/a
Shareholders' equity$48.8M$363.8M$83.8M$169.8M$197.0M

As HALOZYME THERAPEUTICS, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 17, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in HALO's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 5, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeSep 30, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 2.03, 3.02, 9.01Material agreement · Direct financial obligation · Unregistered sale of equitySep 22, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsSep 18, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsSep 16, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeAug 18, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeJul 2, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 11, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteMay 7, 2026
    EDGAR ↗

About HALOZYME THERAPEUTICS, INC.

From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersSAN DIEGO, CA
IncorporatedDE
Former namesHALOZYME THERAPEUTICS INC, GLOBAL YACHT SERVICES INC